home / stock / dyn / dyn articles
Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating...
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during We...
Dyne Therapeutics Inc (NASDAQ: DYN) released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type...
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advan...
GATTI SUSANNA HIGH, Chief Operating Officer at Dyne Therapeutics (NASDAQ:DYN), reported a large insider sell on November 2, according to a new SEC ...
WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on adva...
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on adva...
News, Short Squeeze, Breakout and More Instantly...
2024-06-24 16:00:09 ET Eun Yang from Jefferies issued a price target of $42.00 for DYN on 2024-06-24 12:31:00. The adjusted price target was set to $42.00. At the time of the announcement, DYN was trading at $35.94. The overall price target consensus is at $38.14 with hi...
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Po...
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focuse...